<DOC>
	<DOCNO>NCT01188798</DOCNO>
	<brief_summary>The purpose study determine participant receive GVHD prophylaxis medication pentostatin less severe hepatic toxicity receive MTX . The study estimate sufficient statistical power ascertain least 20 % improvement day 42 NCI CTC grade 2 hepatic toxicity-free survival pentostatin recipient .</brief_summary>
	<brief_title>Methotrexate Pentostatin Graft-versus-host Disease Prophylaxis Risk-adapted Allogeneic Bone Marrow Transplantation Hematologic Malignancies</brief_title>
	<detailed_description>Participants randomize receive either methotrexate ( MTX ) pentostatin graft-versus-host disease ( GVHD ) prophylaxis receive allogeneic bone marrow transplant HLA-matched related unrelated donor . All participant receive standard backbone GVHD prophylaxis regimen ( tacrolimus sirolimus ) conditioning ( cyclophosphamide/TBI ) . A risk-adapted approach use condition minimize risk leukemia relapse base two factor : 1 . Lymphoid versus myeloid primary disease . 2 . KIR compatibility donor host .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>*Age less equal 21 year old High risk malignancy follow : Highrisk ALL CR1 . Examples include , limited : Induction failure &gt; 1 % leukemic lymphoblasts bone marrow remission date ; &gt; 0.1 % leukemic lymphoblasts bone marrow week 7 continuation treatment ( i.e . reinduction I ) ; reemergence leukemic lymphoblast MRD ( level ) patient previously MRD negative ; persistently detectable MRD low level ; early Tcell precursor ( ETP ) ALL . Highrisk ALL beyond CR1 , refractory disease . `` Beyond CR1 '' denote CR follow CR1 , relapse state . `` Refractory disease '' include induction failure . Highrisk de novo AML CR1.Examples include limited : evidence highrisk genetic abnormality highrisk MRD feature . AML beyond CR1 , refractory disease . `` Beyond CR1 '' denote CR follow CR1 , relapse state . `` Refractory disease '' include induction failure . Therapyrelated AML . MDS , primary secondary , stage . NK cell lymphoblastic leukemia CR Biphenotypic bilineage , undifferentiated leukemia . CML phase Hodgkin lymphoma beyond CR1 refractory disease . `` Beyond CR1 '' denote CR follow CR1 , relapse state . NonHodgkin lymphoma beyond CR1 refractory disease . `` Beyond CR1 '' denote CR follow CR1 , relapse state . Juvenile Myelomonocytic Leukemia ( JMML ) . All patient prior evidence CNS leukemia must treat CNS CR eligible study . Has suitable HLA match sibling unrelated volunteer donor available stem cell donation.A `` match '' donor define allele match 7/8 8/8 HLA loci A , B , C DRB1.For purpose study , term `` match sibling '' also refer HLA match family member . Does active malignancy one transplant indicate . Left ventricular ejection fraction &gt; 40 % , shorten fraction &gt; 26 % . Forced vital capacity ( FVC ) great equal 50 % predict value ( correct hemoglobin ) , patient unable perform pulmonary function testing , pulse oximetry great equal 92 % room air . Creatinine clearance great equal 70 ml/min/1.73m2 Karnofsky Lansky ( agedependent ) performance score great equal 70 . Bilirubin le equal 2.5 mg/dL . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase less equal 5 time upper limit normal Not pregnant confirm negative serum urine pregnancy test within 14 day prior enrollment . Not lactate . Has prior allogeneic HSCT . Pregnant lactate female exclude participation short longterm effect protocol intervention infusion fetus nursing child breast milk entirely known time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Allogeneic Bone Marrow Transplantation</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Pentostatin</keyword>
</DOC>